$JAKK

Jakks Pacific Declares Quarterly Cash Dividend to Shareholders

Jakks Pacific (JAKK) has declared a quarterly cash dividend of $0.25 per common share, to be paid on March 30, 2026, to shareholders of record as of February 27, 2026. This move signals the company's confidence in its financial health and commitment to returning capital to shareholders. While an analyst rating on JAKK stock is a Hold with a price target of $19.00, TipRanks' AI Analyst, Spark, rates JAKK as Neutral, citing declining financial performance and challenging market conditions despite a strong balance sheet and attractive dividend yield.

Original reporting
TipRanks · TipRanks Auto-Generated Newsdesk
Published Feb 20, 2026, 2:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 20, 2026, 3:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jakks Pacific Declares Quarterly Cash Dividend to Shareholders — source image
Decision brief

The 30-second read

$JAKKNeutralLow
01

Why it matters

While the dividend may support short-term stock stability, declining financial performance and neutral analyst ratings suggest limited upside.

02

Market read

The news is primarily relevant to current shareholders and investors in the consumer discretionary sector, with limited broader market impact.

03

What to watch

Potential upcoming challenges in the retail market or supply chain issues could offset dividend benefits.

Relevance 6/10Timing: medium

Background

Jakks Pacific has declared a quarterly cash dividend amid mixed financial signals, with a focus on returning capital to shareholders.

Company-level read

Ticker impact

$JAKKNeutralMedium confidence
Context

The news pertains to Jakks Pacific's dividend declaration, indicating financial health and shareholder return policies.

Expected impact

Minor upward pressure in the short term; limited long-term impact without additional positive catalysts.

Evidence & confidence

The dividend indicates positive cash flow, but declining financial metrics and a neutral analyst rating temper enthusiasm.

Market effects

The consumer discretionary sector may experience slight positive sentiment due to dividend announcements, but overall impact is limited.

Minimal regional effects; primarily affecting US-based retail and consumer stocks.

Low; the news is company-specific without broader global implications.

Counterpoint

The dividend could be a sign of limited growth prospects, and the company may be prioritizing shareholder returns over reinvestment.

Key entities

  • Jakks Pacific

    A manufacturer and marketer of toys and consumer products.

Related articles

$JAKKMed

JAKKS Pacific (JAKK) Q2 2026 Earnings Call Transcript

JAKKS Pacific held its Q2 2026 earnings call, saying net sales rose 17% to $139.2M year over year and were $245.9M for the first half, up 6%. International shipping hit $53M for the first half. Gross margin was 32.3%. Operating loss was $142K and adjusted EBITDA was $5.4M. The company said it received essentially all IEPA tariff refunds by Q2 close.

LowAI 8/10

Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne – Thailand Business News

Ascletis Pharma Inc.'s partner, Sagimet Biosciences, has dosed the first patient in a Phase III U.S. trial of denifanstat (ASC40) for moderate to severe acne. The trial aims to enroll 800 patients. Ascletis' prior Phase III trial in China showed ASC40 was more effective than FDA-approved treatments, with 18.6% treatment success vs. 9.4% for sarecycline and 6.7% for doxycycline.